Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-Cytomegalovirus Activity of Maribavir [Camvia] in Recipients of Allogeneic Stem Cell Transplants.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2021
Price :
$35
*
At a glance
- Drugs Maribavir (Primary)
- Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
- Focus Adverse reactions
- Sponsors ViroPharma
- 02 Jun 2008 Results published in Blood, 1 June 2008, previously presented at ASH 2006, Orlando, Florida, USA, 2006.
- 31 Jan 2006 New trial record.